Saudi petrochemicals: the $72 Brent print cuts the desk's H2 2026 earnings read, not just the oil deck

The investment case for the Saudi petrochemical cohort got harder this week, and the reason is the opposite of the headline. Brent printing near 72.95 dollars on June 26, the lowest since February 27, does not by itself cut earnings for companies that buy oil-linked feedstock. The Marsad Research Desk read is that the real downgrade comes from the mechanism behind the oil move, not the oil price. The Strait of Hormuz normalization that dropped crude is the same event that unwinds the abnormal product-spread premium that lifted first-quarter margins off multi-decade lows. Strip that premium out and the cohort's second-half run-rate falls below the Q1 base.

This is the Macro desk's oil print. This desk prices what it does to the forward numbers.

The revision, in numbers

The starting point is the Q1 2026 base. The eight listed Saudi petrochemical producers posted a combined net loss of 244 million dollars in Q1 2026, narrower than the 271 million dollar loss a year earlier (AGBI, June 10, 2026). That improvement was not a demand recovery. SABIC (2010) swung to a net profit of 3.5 million dollars from a 323 million dollar loss, on prices up 6 percent sequentially even as petrochemical sales volume fell 12 percent sequentially. The lift was price, and the price was the Hormuz spread spike: ethylene across Northeast Asia more than doubled during the disruption (C&EN, March 2026).

That is the figure that moves. Old read (Q1 base): spread-inflated margins, the cohort loss narrowing toward breakeven, the best names turning a small profit. New read (the desk's modeled H2 2026): with transit restoring Gulf exports toward 75 percent of prewar levels and the spread premium unwinding, the desk takes second-half cohort margins back below the Q1 run-rate. Implied direction: EPS down across the cohort versus the Q1 annualized base, steepest for the names that were already losing money.

Label this clearly. The 244 million dollar Q1 loss, the SABIC 3.5 million dollar profit, the Saudi Kayan 164 million dollar loss, and the Sipchem 215.3 million riyal loss are sourced facts (AGBI, Argaam). The H2 2026 earnings direction is the Marsad Research Desk's own modeled estimate, built from the oil and spread mechanism, not a broker consensus and not a published target.

The mechanism, named

Three inputs decide the cohort's forward earnings, and only one of them helps. First, feedstock. For non-integrated buyers a lower oil deck lowers naphtha-linked feedstock cost, which is a tailwind. Second, product spreads. The Hormuz spike that doubled ethylene is reversing as vessels transit openly again, which is the dominant headwind and larger than the feedstock benefit. Third, volume. Q1 already showed volume down 12 percent sequentially even with the disruption, so the export normalization helps logistics but does not rebuild demand. Net of the three, the desk reads margin down, not up.

The split inside the cohort is what matters for the read. SABIC (2010), with 70 percent polymers and 30 percent liquids and advantaged integration, holds margin best, which is why Citi sits at a SAR 58 target against the roughly SAR 56 current price, an implied upside near 4 percent (AGBI, June 10, 2026). The loss-makers carry the downside. Saudi Kayan (2350) posted the cohort's worst Q1 at a 164 million dollar net loss, and Sipchem under Sahara International Petrochemical (2310) swung to a 215.3 million riyal loss from a 195.3 million riyal profit a year earlier (Argaam). Those are the names where the desk's H2 markdown bites hardest, because they have the least feedstock advantage to offset the spread reversal.

The stance and what to watch

The desk's stance is that the cohort de-rates on earnings, not on multiple. At roughly SAR 56 SABIC trades inside a 52-week range of 48.20 to 64.00 with an average target near SAR 62, so the screen still shows mid-single-digit to high-single-digit upside. The desk reads that upside as resting on a Q1 base that the spread reversal is about to erode, which means the price has not yet caught the earnings cut. For Kayan and Sipchem, where Q1 was already a loss, the desk sees the H2 risk as widening losses, not narrowing them.

What to watch is the Q2 2026 prints, due into July, which will capture more of the post-normalization spread than the one month Q1 caught. If Q2 margins hold near Q1, the desk's markdown is wrong and the cohort re-rates up. If they fade as transit normalizes, the desk's read is confirmed and the loss-makers lead the move down.

GCC sell-side coverage on these names is thin outside SABIC, where a handful of large brokers set the visible target. Treat the single-broker reads on Kayan and Sipchem as directional, and treat the H2 earnings direction here as the desk's model, shown openly, not borrowed consensus.

Track the cohort's forward margin and valuation against the Q1 base on the Marsad terminal.